



PATENT
671308-2001.1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : FUJIMORI, ET AL
Serial No. : 10/782,899
For : ANAEROBIC BACTERIUM AS A DRUG FOR CANCER
GENE THERAPY
Filed : FEBRUARY 23, 2004
Examiner : WHITEMAN, BRIAN A.
Art Unit : 1635

745 Fifth Avenue
New York, NY 10151

EXPRESS MAIL

Mailing Label Number: EV 195879491 US

Date of Deposit: June 28, 2006

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" Service under 37 CFR 1.10 on the date indicated above and is addressed to: Mail Stop AF, Commissioner for Patents, P.O. Box 1450/Alexandria, VA 22313-1450.

Adams Ahmed

(Typed or printed name of person mailing paper or fee)

A. Ahmed

(Signature of person mailing paper or fee)

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT UNDER 37 C.F.R. §§ 1.97 AND 1.98

Mail Stop AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

The Examiner's attention is respectfully drawn to the documents listed on the accompanying PTO Form 1449.

Pursuant to 37 CFR §1.97, Applicants request the Examiner to consider this Information Disclosure Statement, and to make of record the documents cited on the accompanying PTO

06/30/2006 WASFAW1 00000039 10782899

01 FC:1806

180.00 OP


form 1449 and that a copy of Form PTO-1449 be initialed by the Examiner and returned to the undersigned.

The filing of this Information Disclosure Statement is not an admission that the documents identified herein constitute prior art to the present application.

It is believed that a fee of \$180.00 is required by the instant submission. If additional fees are required for this paper, or if any overpayment has been made, please charge Deposit Acct. No. 50-0320.

Respectfully submitted,
FROMMER LAWRENCE & HAUG LLP

By: Deborah L. Lu
Thomas J. Kowalski
Reg. No. 32,147
Deborah L. Lu
Reg. No. 50,940
Telephone: (212) 588-0800
Facsimile: (212) 588-0500

Based on Form PTO-1449 (3/90) <div style="text-align: center;">  </div>	ATTY. DOCKET NO. <p style="text-align: center;">671308-2001.1</p>	SERIAL NO. <p style="text-align: center;">10/782,899</p>
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)		
APPLICANT <p style="text-align: center;">FUJIMORI, ET AL</p>		
FILING DATE <p style="text-align: center;">FEBRUARY 23, 2004</p>		GROUP <p style="text-align: center;">1635</p>

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
					YES	NO

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

			Li X, Fu GF, Fan YR, Liu WH, Liu XJ, Wang JJ, Xu GX. Bifidobacterium adolescentis as a delivery system of endostatin for cancer gene therapy: selective inhibitor of angiogenesis and hypoxic tumor growth. Cancer Gene Ther. 2003 Feb;10(2):105-11.
			Yi C, Huang Y, Guo ZY, Wang SR. Antitumor effect of cytosine deaminase/5-fluorocytosine suicide gene therapy system mediated by Bifidobacterium infantis on melanoma. Acta Pharmacol Sin. 2005 May;26(5):629-34.

EXAMINER	DATE CONSIDERED
----------	-----------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.